Clinical Data ASCO26: AZ triplet makes waves in frontline liver cancer PharmaphorumEMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.OncologyRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum EMERALD-3 suggests a triplet regimen based on AstraZeneca’s Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CordenPharma inks AmbioPharm buyout to continue peptide production expansionNext: Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
